Rising Infertility Cases Augmenting Female Fertility and Pregnancy Rapid Test Kit Demand

 As per the World Health Organization (WHO), infertility refers to the “failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse”. This is a disease of both the male and female reproductive systems. Infertility is caused by problems in the ejection of semen, abnormal shape and mobility of the sperm, or absence or low levels of sperm in the male reproductive system. Whereas, in the female reproductive system, this disease may be caused by a range of abnormalities of the endocrine system, fallopian tubes, uterus, and ovaries.

Access Report Summary - Female Fertility and Pregnancy Rapid Test Market Size and Value

The WHO estimates that around 48 million couples and 186 million individuals are living with infertility globally. Thus, the surging incidence of infertility is expected to help the female fertility and pregnancy rapid test market progress at a CAGR of 4.5% during 2016–2022. According to P&S Intelligence, the market will generate $489.3 million by 2022. Currently, women dealing with infertility issues are creating a huge requirement for such at-home diagnostic devices owing to their lower cost than laboratory tests.

Essentially, the high number of infertile women is the key factor driving the demand for the associated test kits. As per a study conducted by the WHO, between 1990 and 2012, the global female infertility burden remained almost the same, thus highlighting a high need for diagnoses. The most common examples of abnormal menstruation, which could be a symptom of infertility, affecting the global female population are oligomenorrhea, amenorrhea, and dysmenorrhea. Essentially, family history, smoking, polycystic ovarian syndrome (PCOS), premature ovarian insufficiency, and impaired hypothalamus and pituitary gland function can cause female infertility.

Geographically, North America will dominate the female fertility and pregnancy rapid test market in the foreseeable future due to the soaring incidence of uterine fibroids and PCOS. Additionally, the female population of the region is experiencing irregular and heavy bleeding, abnormalities of the uterus, and indescribable miscarriages, owing to which North America is witnessing a considerable use of such kits. As per the Centers for Disease Control and Prevention (CDC), “About 6% of married women aged 15 to 44 years in the United States are unable to get pregnant after one year of trying (infertility).”

Therefore, the burgeoning infertile female population will boost the adoption of fertility and pregnancy rapid test kits.